<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1000083763474443&amp;ev=PageView&amp;noscript=1">

Orthofix Cites SmartTRAK in Q219 Earnings Call and Press Release

Posted by Lindsey Wolejko on 8/8/19 11:01 AM

St Orthofix Logos-1SmartTRAK was once again cited as a trusted source for market data, this time in the Orthofix Q219 Earnings Call and press release.

Brad Mason, Orthofix's President and Chief Executive Officer, referenced the SmartTRAK Market Recap: OrthoBio Report in the press release and stated “Regarding the second quarter results, net sales were in line with our expectations, led by another quarter of outstanding performance in our Biologics products and notably, as reported by SmartTRAK®, Orthofix now has the number one market share position in the U.S. cellular allograft segment.”

On the Earnings Call, Mr Mason said "Also, we are pleased to report that based on recent SmartTRAK data, we believe that we have now achieved the number one position in the cellular allograft market, with over $100 million of sales to hospitals in the last 12 months. Based on our first half performance, we now expect our full year sales growth expectations to be in the high single digits for this business."

SmartTRAK was also cited as a source in a recent Smith & Nephew press release regarding their meniscal knee repair technology.

SmartTRAK is the leading source of competitive intelligence used by the top ten global orthopedic & wound care companies.  If you would like a demo of what SmartTRAK has to offer and how we can help increase proficiency, improve productivity and reduce costs for your company, just click the button below.

 

Request a Demo of the SmartTRAK 
Business Intelligence 
Portal!

 

Topics: OrthoBio

Subscribe to News and Analysis Blog Weekly Emails

SmartTRAK is the leading source of competitive intelligence used by the top ten global orthopedic and wound care companies. 

Recent Posts